Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers

Pediatr Blood Cancer. 2014 Jun;61(6):1074-9. doi: 10.1002/pbc.24947. Epub 2014 Jan 25.

Abstract

Objective: In children, CNS-directed cancer therapy is thought to result in decreased cerebral white matter volumes (WMV) and subsequent neurocognitive deficits. This study was designed as a prospective validation of the purported reduction in WMV, associated influential factors, and its relationship to neurocognitive deficits in a very large cohort of both acute lymphoblastic leukemia (ALL) and malignant brain tumors (BT) survivors in comparison to an age similar cohort of healthy sibling controls.

Procedures: The effects of host characteristics and CNS treatment intensity on WMV were investigated in 383 childhood cancer survivors (199 ALL, 184 BT) at least 12 months post-completion of therapy and 67 healthy siblings that served as a control group. t-Tests and multiple variable linear models were used to assess cross-sectional WMV and its relation with neurocognitive function.

Results: BT survivors had lower WMV than ALL survivors, who had less than the control group. Increased CNS treatment intensity, younger age at treatment, and greater time since treatment were significantly associated with lower WMV. Additionally, cancer survivors did not perform as well as the control group on neurocognitive measures of intelligence, attention, and academic achievement. Reduced WMV had a larger impact on estimated IQ among females and children treated at a younger age.

Conclusions: Survivors of childhood cancer that have undergone higher intensity therapy at a younger age have significantly less WMV than their peers and this difference increases with time since therapy. Decreased WMV is associated with significantly lower scores in intelligence, attention, and academic performance in survivors.

Keywords: cancer survivors; childhood ALL; computer-assisted image analysis; magnetic resonance imaging; malignant primary brain tumors; neuropsychology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Attention
  • Attention Deficit Disorder with Hyperactivity / drug therapy
  • Attention Deficit Disorder with Hyperactivity / epidemiology*
  • Attention Deficit Disorder with Hyperactivity / etiology
  • Attention Deficit Disorder with Hyperactivity / pathology
  • Brain / drug effects
  • Brain / pathology
  • Brain / radiation effects
  • Brain Damage, Chronic / drug therapy
  • Brain Damage, Chronic / epidemiology
  • Brain Damage, Chronic / etiology
  • Brain Damage, Chronic / pathology
  • Brain Neoplasms / complications*
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / radiotherapy
  • Child
  • Child, Preschool
  • Cranial Irradiation / adverse effects*
  • Cross-Sectional Studies
  • Educational Status
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Spinal
  • Intelligence
  • Learning Disabilities / epidemiology*
  • Learning Disabilities / etiology
  • Learning Disabilities / pathology
  • Leukoencephalopathies / epidemiology*
  • Leukoencephalopathies / etiology
  • Leukoencephalopathies / pathology
  • Magnetic Resonance Imaging
  • Male
  • Methylphenidate / therapeutic use
  • Neuropsychological Tests
  • Organ Size
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • Prognosis
  • Prospective Studies
  • Radiation Injuries / epidemiology
  • Radiation Injuries / etiology
  • Radiation Injuries / psychology
  • Risk
  • Survivors* / psychology

Substances

  • Antineoplastic Agents
  • Methylphenidate